ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Incidence and Outcomes of CMV Infection in Pancreas Transplant with Thymoglobulin Induction: A Single Center Experience

W. Abusalah, A. Yadav

Thomas Jefferson University Hospital, Philadelphia, PA

Meeting: 2022 American Transplant Congress

Abstract number: 1180

Keywords: Cytomeglovirus, Immunosuppression, Infection, Pancreas transplantation

Topic: Clinical Science » Pancreas » 65 - Pancreas and Islet: All Topics

Session Information

Session Name: Pancreas and Islet: All Topics

Session Type: Poster Abstract

Date: Sunday, June 5, 2022

Session Time: 7:00pm-8:00pm

 Presentation Time: 7:00pm-8:00pm

Location: Hynes Halls C & D

*Purpose: CMV infection is a major infectious complication in pancreas transplant recipients (PTR). Incidence of CMV viremia in PTR with thymoglobulin induction and it’s effect on graft survival is not well studied. Here, we aim to review the incidence and outcomes of CMV viremia in this patient population.

*Methods: A single-center, retrospective analysis of 39 PTR [including simultaneous kidney pancreas (SPK), pancreas only, pancreas after kidney or kidney after pancreas] between November 2016- April 2021 with thymoglobulin induction (6 mg/kg) with ≥8 months of follow-up (excluding one PTR due to death from postoperative complications). PTRs were on tacrolimus, mycophenolate +/- steroids for maintenance immunosuppression (IS) and one on azathioprine instead of mycophenolate. For CMV prophylaxis, valganciclovir was prescribed for 180 days in high-risk serostatus (donor- positive/recipient-negative; D+/R-), 90 days for moderate-risk (D -/R + or D+/ R+) and 30 days for low-risk (D-/ R-) per our institution’s protocol. Management of CMV viremia included reducing IS, oral valganciclovir or intravenous ganciclovir depending on the titers, response, and presence of CMV disease. Foscarnet and/ or cytogam were used in 2/9 patients based on their response to standard treatment.

*Results: CMV viremia was reported in 9/38 (23%) PTRs, all of which occurred in the first year post-transplant and all were SPK PTRs. 8/9 (88%) were in the CMV high-risk serostatus group. Pancreas allograft rejection or failure (according to UNOS definition) was not reported in CMV infected PTRs compared to two in non-infected PTRs. CMV infection did not result in a severe clinical course (ICU admission or death). Age, gender, race, antigen mismatch or pancreas donor risk index (PDRI) did not affect the incidence of CMV infection, but higher cold-ischemic time was noted in viremic group. Steroids as part of maintenance IS, did not affect incidence of CMV viremia either. We noted 2/9 CMV infected PTRs had post-transplant diabetes (defined as initiation of oral hypoglycemic agents or insulin< 0.5 u/kg/day) compared to none in non-infected group.

*Conclusions: Our study suggests higher CMV incidence in the first year post-transplant and in the SPK group. CMV viremia in PTR did not affect patient or graft survival, however, higher rates of PTD were noted in the viremic group. In our experience, most patients can be successfully treated with decreased immunosuppression and PO valganciclovir or IV ganciclovir.

Comparing demographic and transplant characteristics amongst PTR with and without CMV viremia
CMV viremia (N = 9) No CMV Viremia (N= 29)
Age in years (Median) 41 44.2
Race (%)Black Hispanic White Asian 12%44%44%0% 37%0%58%3%
Pancreas allograft failure 0% 7%
Post-transplant diabetes mellitus 11% 0%
Antigen mismatch (0-2)(3-4)(5-6) 11%33%55% 0%20.4%79%
Cold ischemia Time in hours (Mean) 12.4 10.7
Pancreas donor profile index (PDRI)(< 20%)(20%-80%) 66%33% 65%34.4%
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Abusalah W, Yadav A. Incidence and Outcomes of CMV Infection in Pancreas Transplant with Thymoglobulin Induction: A Single Center Experience [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/incidence-and-outcomes-of-cmv-infection-in-pancreas-transplant-with-thymoglobulin-induction-a-single-center-experience/. Accessed May 30, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences